INT86672

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 2000
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 50
Total Number 50
Disease Relevance 34.16
Pain Relevance 8.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Bcl2) aging (Bcl2) cell morphogenesis (Bcl2)
endoplasmic reticulum (Bcl2) intracellular (Bcl2) response to stress (Bcl2)
Anatomy Link Frequency
Bone marrow 2
brain 2
neuronal 2
liver 1
fibroblasts 1
Bcl2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Spinal cord 29 99.68 Very High Very High Very High
Opioid 16 99.36 Very High Very High Very High
Dorsal horn 2 99.20 Very High Very High Very High
qutenza 11 98.76 Very High Very High Very High
amygdala 5 98.48 Very High Very High Very High
Morphine 23 98.20 Very High Very High Very High
Glutamate 147 97.76 Very High Very High Very High
antidepressant 7 97.32 Very High Very High Very High
cINOD 25 97.00 Very High Very High Very High
depression 3 96.52 Very High Very High Very High
Disease Link Frequency Relevance Heat
Apoptosis 784 100.00 Very High Very High Very High
Stress 176 99.98 Very High Very High Very High
Death 342 99.92 Very High Very High Very High
Hypoxia 47 99.76 Very High Very High Very High
Cerebral Hypoxia 8 99.62 Very High Very High Very High
Ganglion Cysts 17 99.54 Very High Very High Very High
Injury 150 99.46 Very High Very High Very High
Hepatocellular Cancer 6 98.92 Very High Very High Very High
Stomach Cancer 4 98.38 Very High Very High Very High
Autism 164 98.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In this study, the increase of apoptosis in retinal ganglion cells was linked to a downregulation of the Bcl-2:Bax ratio.
Negative_regulation (downregulation) of Bcl-2 in retinal ganglion cells associated with ganglion cysts and apoptosis
1) Confidence 0.53 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2765238 Disease Relevance 0.61 Pain Relevance 0.09
Furthermore, our results do not exclude Bcl-2 downregulation after 24 h.
Negative_regulation (downregulation) of Bcl-2
2) Confidence 0.53 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2765238 Disease Relevance 0.37 Pain Relevance 0.03
In adult rats, exposure to unpredictable stress reduced Bcl-2 mRNA levels in the central nucleus of the amygdala (CeA), cingulate (Cg), and frontal (Fr) cortices.
Negative_regulation (reduced) of Bcl-2 mRNA in CeA associated with stress and amygdala
3) Confidence 0.53 Published 2008 Journal Neuropsychopharmacology Section Abstract Doc Link 17700647 Disease Relevance 0.96 Pain Relevance 0.46
Multiple nonclinical models demonstrate the effects of oblimersen, including reduced Bcl-2 levels, reduced cell viability, increased activity of apoptotic mechanisms, reduction in tumor size, and enhanced activity of cytotoxic anticancer drugs (Klasa et al 2002).
Negative_regulation (reduced) of Bcl-2 associated with cancer and apoptosis
4) Confidence 0.47 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 0.63 Pain Relevance 0
Patients who achieved a complete response showed decreases in median bcl-2 mRNA and protein levels relative to baseline.
Negative_regulation (decreases) of bcl-2
5) Confidence 0.47 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 0.28 Pain Relevance 0
Uptake of oblimersen into patient cells with subsequent decreases in bcl-2 RNA and Bcl-2 protein has been documented in patients with acute myeloid leukemia (Marcucci et al 2005), but has not yet been assessed in patients with CLL.
Negative_regulation (decreases) of Bcl-2 associated with chronic lymphoid leukemia and leukemia
6) Confidence 0.47 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 1.11 Pain Relevance 0
Reduction of Bcl-2 protein levels in peripheral blood mononuclear cells was observed in pediatric patients with solid tumors after administration of oblimersen at doses of 3, 5, and 7 mg/kg/d (Rheingold et al 2007).
Negative_regulation (Reduction) of Bcl-2 in blood associated with solid tumor
7) Confidence 0.47 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 0.77 Pain Relevance 0
Among the 8 patients, downregulation of bcl-2 mRNA in bone marrow was observed in 4 patients; bcl-2 mRNA was unchanged in 2 patients and increased in 2 patients.
Negative_regulation (downregulation) of bcl-2 in bone marrow
8) Confidence 0.47 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 0.20 Pain Relevance 0
Bcl-2 protein levels were reduced by Day 5 in 9 of 15 patients, including 6 of 9 patients treated with oblimersen 3 mg/kg/d, as shown in Figure 1.


Negative_regulation (reduced) of Bcl-2
9) Confidence 0.47 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 1.08 Pain Relevance 0
Results suggest a correlation between clinical outcome and the antisense activity of oblimersen as measured by bcl-2 mRNA downregulation and Bcl-2 protein levels.
Negative_regulation (downregulation) of bcl-2
10) Confidence 0.47 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 0.83 Pain Relevance 0
However, this decrease was associated with a marked reduction in Bcl-2 rather than with an increase in Bax itself [24].
Negative_regulation (reduction) of Bcl-2
11) Confidence 0.47 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2765238 Disease Relevance 0.58 Pain Relevance 0.09
Accordingly, the ratio of bcl-2 to bax was reduced in the reperfused area, indicating a pro-apoptotic trend.
Negative_regulation (reduced) of bcl-2 associated with apoptosis
12) Confidence 0.42 Published 2001 Journal Jpn Heart J Section Abstract Doc Link 11933925 Disease Relevance 0.49 Pain Relevance 0.14
The results showed a significant increase in Bax immunoreactivity in all of the mentioned embryonic days (E9.5 to E13.5) and a significant decrease in Bcl-2 immunoreactivity at days E10.5 and E12.5 in morphine-treated groups compared with control.
Negative_regulation (decrease) of Bcl-2 associated with morphine
13) Confidence 0.42 Published 2010 Journal J. Mol. Neurosci. Section Abstract Doc Link 19936637 Disease Relevance 0.20 Pain Relevance 0.73
The increase in pro-apoptotic Bad proteins, the decrease in anti-apoptotic Bcl-2 proteins, and caspase activation were all suppressed in the 7018-RGM-1 cells.
Negative_regulation (decrease) of Bcl-2
14) Confidence 0.42 Published 2009 Journal Digestion Section Body Doc Link 19401612 Disease Relevance 0.20 Pain Relevance 0
In this study, we found that suppression of Bcl-2 showed increased number of necrotic cells ad apoptosis.
Negative_regulation (suppression) of Bcl-2 associated with apoptosis
15) Confidence 0.42 Published 2009 Journal Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association Section Body Doc Link PMC2841413 Disease Relevance 1.34 Pain Relevance 0.15
Nonetheless, in street heroin-treated cortical neurons, cytochrome c was released, accompanied by a decrease in mitochondrial potential and Bcl-2/Bax.
Negative_regulation (decrease) of Bcl-2 in neurons
16) Confidence 0.41 Published 2007 Journal J. Neurochem. Section Abstract Doc Link 17250679 Disease Relevance 0.56 Pain Relevance 0.15
Results suggest a correlation between clinical outcome and the antisense activity of oblimersen as measured by bcl-2 mRNA downregulation and Bcl-2 protein levels.
Negative_regulation (downregulation) of Bcl-2
17) Confidence 0.35 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 0.83 Pain Relevance 0
Bone marrow aspirates from 12 patients were assessed for bcl-2 mRNA, of which 9 (75%) showed downregulation.
Negative_regulation (downregulation) of bcl-2 in Bone marrow
18) Confidence 0.35 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 0.16 Pain Relevance 0
Uptake of oblimersen into patient cells and downregulation of bcl-2 mRNA with a decrease in Bcl-2 protein has been demonstrated in clinical studies.
Negative_regulation (decrease) of Bcl-2
19) Confidence 0.35 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 0.18 Pain Relevance 0
Uptake of oblimersen into patient cells with subsequent decreases in bcl-2 RNA and Bcl-2 protein has been documented in patients with acute myeloid leukemia (Marcucci et al 2005), but has not yet been assessed in patients with CLL.
Negative_regulation (decreases) of bcl-2 associated with chronic lymphoid leukemia and leukemia
20) Confidence 0.35 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 1.10 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox